Ideas
Large-cap Korean leaders can keep outperforming.
The KOSPI rally is likely to remain concentrated in large caps with visible earnings and structural growth stories rather than broad small-cap participation. Investors should follow companies that can prove numbers and raise guidance, as the market is increasingly differentiating between re-rated leaders and laggards.
Buy Samsung and SK Hynix.
Memory shortage and supplier-friendly conditions since the second half of 2025 have re-rated Samsung Electronics and SK hynix. The recent pullback looks minor versus prior gains, and the January 29 earnings and conference calls, especially HBM4 qualification roadmaps and Samsung’s foundry loss reduction, could restart a strong rally; dips are opportunity.
Hyundai's robotics roadmap supports re-rating.
Hyundai Motor's move beyond automaking into physical AI with Boston Dynamics and an explicit 2028 Atlas rollout roadmap supports structural re-rating. Although UBS cut to neutral with a 490,000 won target on valuation, other targets of 620,000 to 680,000 won and the market’s focus on the robotics roadmap keep the upside case intact.
Korean robotics re-rating has further room.
Robotics and physical AI are becoming a key structural theme as Hyundai Motor presents an Atlas roadmap, LG Electronics moves from appliances to robot platforms, and POSCO enters industrial robots. This is creating a re-rating wave across robot-related Korean large caps and components.
LG Electronics shifts toward robot platforms.
LG Electronics is being re-rated from a home-appliance maker into a robot platform company. Its robot-industry entry and target-price hikes show the market is assigning value to this structural shift.
POSCO gains industrial robot exposure.
POSCO's collaboration with a Japanese company to enter the industrial robot market gives it new robotics and physical-AI project exposure, supporting the broader Korean robot re-rating theme.
Korean defense names have earnings visibility.
Korean defense and aerospace is favored for clear earnings visibility, global rearmament and geopolitical risk, with foreign investors buying Hanwha Aerospace and Korea Aerospace Industries. Hanwha Aerospace received a 1.8 million won target and is expected to see a wave of 2026 orders; Hyundai Rotem and LIG Nex1 still have room to prior highs.
Shipbuilding earnings visibility remains strong.
Korean shipbuilding has clear earnings visibility, strong order backlogs, and competitive delivery and pricing advantages. The speaker expects shipbuilders to regain strength during the earnings season.
Korean nuclear exports have competitive edge.
Korea's nuclear power industry has technological strength, faster delivery, and competitive pricing, making it one of Korea's advantaged export sectors amid global supply-chain realignment.
Tax reform may favor Korean dividend stocks.
If the government implements dividend separate taxation and adjusts the maximum tax rate, dividend stocks should become more attractive in the second half. Companies that respond with shareholder returns could be selected even after some pre-emptive moves.
Samsung Electro-Mechanics leads substrate-robot re-rating.
Samsung Electro-Mechanics is an overlooked but strong earnings and growth name with MLCC sales and PCB substrate momentum, 100% utilization, and humanoid robot camera and actuator investments. Its strength could act as a trigger for substrate and robot-related names, including LG Innotek, which trades as a pair.
Samsung Biologics can revive biotech sentiment.
Samsung Biologics remains the global CDMO leader and its fourth quarter should combine high growth and high profitability: revenue up about 30% year over year and operating margin in the mid-40% range, helped by large-scale capacity and process efficiency despite one-off costs. Its spin-off may also clarify core-business value, potentially reviving biotech sentiment.
Wait for Alteogen's actual tech-transfer deal.
Alteogen is an event-driven technology-transfer watch: multiple licensing talks are reportedly underway, but no deal has been announced, and the stock faded after a one-day pop. The speaker suggests waiting for an actual technology-transfer announcement before treating it as a trend reversal.
Korean biotech rotation needs tech-transfer trigger.
Korean biotech and pharma has underperformed but is attracting rotation flows when large caps rest. A sustained move needs Samsung Biologics' earnings visibility, at least one major technology-transfer deal, and stronger policy support; otherwise rallies may remain short-lived.
Cosmetics recovery hinges on Q4 results.
Korean cosmetics has been deeply underperformed except for APR, with Chinese low-cost competition and US tariffs pressuring the old model. Fourth-quarter results are the key test for whether companies pivoting to Europe and Japan can restore earnings visibility; if recovery appears, selective low-buying is possible, otherwise the old rally is unlikely.
Amorepacific faces structural China competition.
Amorepacific and other traditional China-dependent cosmetics names remain structurally challenged: Chinese local brands can produce similar products cheaply, and large corporate decision-making is too slow for fast-moving cosmetics trends. Recovery will be difficult.
This 3PRO TV (삼프로TV) video, published January 20, 2026,
features Lee Ji-eun
discussing Korean large-cap stocks, 005930.KS, 000660.KS, 005380.KS, Korean robotics sector, 066570.KS, 005490.KS, 012450.KS, 047810.KS, 064350.KS, 079550.KS, Korean shipbuilding sector, Korean nuclear power sector, Korean dividend stocks, 009150.KS, 011070.KS, 207940.KS, 196170.KQ, Korean Biotech/Pharma Sector, KORU, 090430.KS.
16 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Lee Ji-eun
· Tickers:
Korean large-cap stocks,
005930.KS,
000660.KS,
005380.KS,
Korean robotics sector,
066570.KS,
005490.KS,
012450.KS,
047810.KS,
064350.KS,
079550.KS,
Korean shipbuilding sector,
Korean nuclear power sector,
Korean dividend stocks,
009150.KS,
011070.KS,
207940.KS,
196170.KQ,
Korean Biotech/Pharma Sector,
KORU,
090430.KS
